The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
22336
Nole
v0id
Kao
OK
didiwang
yjh123
ale
愉快的真
Yuki
丰富语蕊
Oracle
行走的荷尔蒙
嘻嘻哈哈
渡人舟
昏睡的蟠桃
初景
GingerF
sagitar
皖公网安备34019202002308
